



Preferred Drug List

NEW DRUG REVIEW

Proprietary Name: Zioptan™

Common Name: Tafluprost

PDL Category: Ophthalmic Prostaglandins

<u>Comparable Products</u>	<u>Preferred Drug List Status</u>
Latanoprost	Preferred
Lumigan®	Preferred
Travatan Z®	Preferred

Summary

Indications and Usage: Indicated to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.¹

Mechanism of Action: Selective FP prostanoid receptor agonist which is believed to reduce intraocular pressure by increasing uveoscleral outflow.¹

Dosage Forms: Ophthalmic Solution: 0.015mg/ml

Recommended Dosage: Instill one drop into the affected eye(s) once daily in the evening.¹

Common Adverse Drug Reactions: Conjunctival hyperemia.¹

Contraindications: None.¹

Manufacturer: Merck & Co., Inc.

Analysis: Zioptan™ is a new preservative free ophthalmic prostaglandin indicated to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In the trials used to gain FDA approval, Zioptan™ lowered intraocular pressure (IOP) at 3 and 6 months by 6-8 mmHg and 5-8mmHg respectively. In comparison, latanoprost reduced IOP by 6-8 mmHg, and Lumigan® and Travatan Z® by 7-8 mmHG in clinical studies. Preferred alternatives appear on the Preferred Drug List which have similar clinical efficacy and are more cost effective. Therefore, it is recommended that Zioptan™ be added to the Preferred Drug List as a non-preferred drug.

IME Recommendation:

<input type="checkbox"/> Preferred Drug	<input type="checkbox"/> Recommended Drug
<input checked="" type="checkbox"/> Non-Preferred Drug	<input type="checkbox"/> Non-Recommended Drug
<input type="checkbox"/> Preferred Drug with Conditions	

1. Zioptan™ [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2012.